G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer

PURPOSE: The combination of targeting the CDK4/6 and estrogen receptor (ER) signaling pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of ER-positive breast cancer. However, the poor physicochemical properties of fulvestrant require monthly intramuscular i...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Breast Cancer Res Treat
Main Authors: Andreano, Kaitlyn J., Wardell, Suzanne E., Baker, Jennifer G., Desautels, Taylor K., Baldi, Robert, Chao, Christina A., Heetderks, Kendall A., Bae, Yeeun, Xiong, Rui, Tonetti, Debra A., Gutgesell, Lauren M., Zhao, Jiong, Sorrentino, Jessica A., Thompson, Delita A., Bisi, John E., Strum, Jay C., Thatcher, Gregory R. J., Norris, John D.
Formato: Artigo
Idioma:Inglês
Publicado: Springer US 2020
Assuntos:
Preclinical Study
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7103015/
https://ncbi.nlm.nih.gov/pubmed/32130619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05575-9
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares